A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

Inclusion criteria

• ✓. has a negative urine pregnancy test and agrees to use one of the accepted contraceptive regimens throughout the entire duration of the trial from screening until last follow-up visit. The following contraceptive measures are considered adequate:
• ✓. Combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal).
• ✓. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable).
• ✓. Placement of an intrauterine device or intrauterine hormone-releasing system.
• ✓. Bilateral tubal occlusion.
• ✓. Barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository).
• ✓. Has a vasectomized or sterile partner (where partner is sole partner of subject) and where vasectomy has been confirmed by medical assessment.
• ✓. Exercises true sexual abstinence. Sexual abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.